AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Stock analysts at Leerink Swann boosted their Q3 2017 earnings per share (EPS) estimates for AMAG Pharmaceuticals in a research report issued to clients and investors on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the specialty pharmaceutical company will earn ($0.36) per share for the quarter, up from their prior forecast of ($0.43). Leerink Swann also issued estimates for AMAG Pharmaceuticals’ FY2017 earnings at ($2.16) EPS, FY2018 earnings at ($5.96) EPS and FY2019 earnings at ($0.02) EPS.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The firm had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. During the same period in the prior year, the company earned $1.45 EPS. The firm’s revenue was up 24.3% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: “AMAG Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($0.36) Per Share, Leerink Swann Forecasts (AMAG)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/08/22/amag-pharmaceuticals-inc-to-post-q3-2017-earnings-of-0-36-per-share-leerink-swann-forecasts-amag.html.

AMAG has been the topic of a number of other research reports. Barclays PLC restated a “hold” rating and set a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 25th. TheStreet downgraded shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Citigroup Inc. cut their price target on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Finally, Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 26th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and an average price target of $28.09.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 17.60 on Monday. AMAG Pharmaceuticals has a 12 month low of $16.00 and a 12 month high of $36.83. The stock’s market capitalization is $621.07 million. The company’s 50-day moving average is $18.86 and its 200-day moving average is $20.50.

In related news, SVP Julie Krop sold 4,938 shares of the firm’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares in the company, valued at approximately $566,720. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.80% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sei Investments Co. raised its stake in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock valued at $188,000 after buying an additional 54 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in AMAG Pharmaceuticals by 1.4% in the first quarter. Louisiana State Employees Retirement System now owns 14,000 shares of the specialty pharmaceutical company’s stock valued at $316,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System raised its stake in AMAG Pharmaceuticals by 1.7% in the first quarter. Arizona State Retirement System now owns 17,900 shares of the specialty pharmaceutical company’s stock valued at $404,000 after buying an additional 300 shares in the last quarter. Nordea Investment Management AB raised its stake in AMAG Pharmaceuticals by 1.1% in the second quarter. Nordea Investment Management AB now owns 37,200 shares of the specialty pharmaceutical company’s stock valued at $684,000 after buying an additional 400 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in AMAG Pharmaceuticals by 0.7% in the second quarter. Teachers Advisors LLC now owns 62,481 shares of the specialty pharmaceutical company’s stock valued at $1,150,000 after buying an additional 426 shares in the last quarter.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Earnings History and Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.